Evidence map›Paper›PMID 27429042›Full record

ArticleOncotarget2016

Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism.

Mariona Jové, Sònia Gatius, Andree Yeramian, Manuel Portero-Otin, Núria Eritja, Maria Santacana, Eva Colas, Maria Ruiz, Reinald Pamplona, Xavier Matias-Guiu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Cannabinoids in Gynecological Diseases.Medical cannabis and cannabinoids · 2019
    Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mariona JovéDepartment of Experimental Medicine, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Sònia GatiusDepartment of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Andree YeramianDepartment of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Manuel Portero-OtinDepartment of Experimental Medicine, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Núria EritjaDepartment of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Maria SantacanaDepartment of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Eva ColasDepartment of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Maria RuizDepartment of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Reinald PamplonaDepartment of Experimental Medicine, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Xavier Matias-GuiuDepartment of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, E-25198, Lleida, Spain.
Universitat de Lleida · ESBiomedical Research Institute of Lleida · ESHospital Universitari Arnau de Vilanova · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolomics, an essential technique in precision medicine, contributes to the molecular fingerprinting of tumours, further helping to understand their pathogenesis. In this work, using a LC-ESI-QTOF-MS/MS platform, we demonstrated the existence of a specific metabolomic signature which could define endometrioid endometrial carcinoma (EEC), arising the endocannabinoid system as a potential pathway involved in EC pathogenesis. Metabolomics could also shed light in the processes involved in myometrial invasion, proposing new targets for possible therapeutic intervention. Consequently, we also described a different metabolomic profile in surface endometrioid carcinoma and myometrial invasive front. We validated pathways disclosed by metabolomics by immunohistochemistry. Specifically, endocannabinoid and purine metabolism could be involved in tumor myometrial invasion.

Indexed as

Biomarkers, TumorCarcinoma, EndometrioidEndocannabinoidsEndometrial NeoplasmsFemaleHumansMetabolomicsBiomarkers, TumorEndocannabinoidsendocannabinoid systemendometrioid endometrial carcinomamass spectrometrymetabolomic profilepersonalized medicine

Identifiers

PMID27429042
PMCPMC5239558
OpenAlexW2474079286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.